• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Teal Health Expands Nationwide – Bringing FDA Authorized At-Home Cervical Cancer Screening to All 50 States

by Syed Hamza Sohail 01/07/2026 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Teal Health, a virtual women’s health company on a mission to eliminate cervical cancer in the U.S., today announced the national availability of its comprehensive telehealth platform and its FDA-authorized self-collection device for at-home cervical cancer screening, the Teal Wand™. Cervical cancer screening, often referred to as the pap smear, is a recommended screening for all women ages 25-65. 

– In May 2025, Teal received FDA-authorization, and now just seven months later, has scaled nationally to meet the growing demand, in lockstep with the newly published update to the American Cancer Society’s (ACS) cervical cancer screening guidelines.

Expanding Access Through Guideline-Backed Innovation

Teal Health is a woman-led company advancing a simple but overdue idea in women’s health: cervical cancer screening that meets patients where they are. With the first FDA-authorized vaginal self-collection device for at-home primary HPV testing now available across all 50 states, Teal is reframing how—and where—screening can happen.

This momentum is reinforced by national alignment. In a recent update, the American Cancer Society added at-home self-collection using the Teal Wand as a recommended option for primary HPV testing. Teal is also a member of the Cervical Cancer Roundtable, a joint collaboration between the ACS and the Cancer Moonshot, underscoring a shared goal: eliminate cervical cancer as a public health concern in the United States.

Starting today, women can order a kit directly via getteal.com. Licensed providers confirm eligibility through a brief virtual visit, prescribe the kit, and guide the process end-to-end:

  • Private sample collection at home using the Teal Wand
  • Mail-in testing with the same FDA-approved HPV assay used in clinics
  • Secure results delivery and virtual follow-up for abnormal findings
  • Optional coordination with an existing OB-GYN or primary care team (with consent)

The result is clinical parity with clinic-based testing—without the logistical, emotional, or access barriers that keep many women from screening.

Cervical cancer is nearly 100% preventable with routine screening, yet almost one in three U.S. women is behind, and participation has declined over the past decade. Missed appointments, discomfort, and prior trauma continue to drive under-screening. Teal’s model removes friction while preserving rigor.

Evidence from other cancers shows what happens when screening is made easier. At-home colorectal cancer screening has been embedded in U.S. guidelines since 2016, with participation gains translating into real outcomes. A long-running mailed outreach program at Kaiser Permanente more than doubled screening rates over time and halved mortality—proof that access and adherence scale together.

Teal’s own data are equally compelling. In a 16-site national clinical trial, Teal Wand performance matched clinician-collected samples, detecting cervical precancer 96% of the time. Patient experience followed suit: 94% preferred the Teal Wand for comfort, ease, and privacy. Early real-world users echo that finding, rating the experience 4.9 stars and describing it as quick, painless, and transformative.

Operationally, Teal works with most major insurers and supports HSA/FSA payments. Pricing is $99 with in-network insurance and $249 without, with active efforts underway to expand coverage and reduce out-of-pocket costs. Parallel partnerships with health systems, employers, and provider organizations aim to reach women who are overdue or face structural barriers in traditional care settings.

Leadership sees the moment clearly. “Meeting overwhelming demand so soon after FDA authorization is both validating and motivating,” said Kara Egan, CEO and Co-Founder. “Women have been asking for a better option—and now it’s here.”

In January, aligned with Cervical Cancer Awareness Month, Teal convened 30 female-focused companies and healthcare organizations around a simple call to action: however you say it—HPV test, Pap, cervical cancer screening—don’t delay it. Teal’s nationwide launch turns that message into an accessible, guideline-backed reality.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |